If You Invested in AbbVie Inc. (ABBV)

AbbVie Inc. (NYSE: ABBV) is a pharmaceutical company in the pharmaceutical preparation manufacturing industry. According to its public statements, AbbVie’s mission is to discover and deliver medicines and solutions that address serious health issues and medical challenges. The company focuses on several key therapeutic areas, including immunology, oncology, neuroscience, and eye care, and also offers products and services in its Allergan Aesthetics portfolio.

AbbVie’s common stock trades on the New York Stock Exchange under the ticker symbol ABBV, and the company has multiple series of senior notes listed on the same exchange. Regulatory filings identify AbbVie Inc. as based in North Chicago, Illinois. Through its activities in research, development, manufacturing and commercialization of medicines, AbbVie participates in the broader manufacturing sector with a specific focus on pharmaceutical preparation.

Therapeutic focus and portfolio

Company disclosures emphasize AbbVie’s work across immunology, oncology, neuroscience and eye care. In oncology, AbbVie describes an expansive portfolio and pipeline that spans blood cancers and solid tumors. The company reports that it is advancing investigational therapies and approved medicines across modalities such as T-cell engagers, BCL-2 inhibitors and antibody-drug conjugates (ADCs), as well as immuno-oncology-based therapeutics and multispecific antibodies. AbbVie also highlights its Allergan Aesthetics portfolio as part of its overall offering.

AbbVie has stated that it is evaluating numerous investigational medicines in clinical trials for a range of cancers, including multiple myeloma, follicular lymphoma, chronic lymphocytic leukemia, diffuse large B‑cell lymphoma, acute myeloid leukemia and amyloidosis. The company also reports approved therapies such as EPKINLY (epcoritamab-bysp) and VENCLEXTA (venetoclax), which are being studied further in additional indications. In immunology and neuroscience, AbbVie has referenced current and next‑generation medicines supported by its manufacturing investments in the United States.

Business activities and collaborations

AbbVie engages in research and development (R&D), manufacturing, and commercialization of pharmaceutical products. Public news releases describe collaborations, licensing agreements and acquisitions that are intended to expand its pipeline and manufacturing capabilities. For example, AbbVie has announced an exclusive licensing agreement with RemeGen for RC148, a novel investigational PD‑1/VEGF bispecific antibody for advanced solid tumors, and has described RC148 as strengthening its oncology portfolio and creating opportunities for combination regimens with AbbVie’s ADCs.

The company has also announced a definitive agreement to acquire a device manufacturing facility in Tempe, Arizona and associated intellectual property from West Pharmaceutical Services. AbbVie states that this acquisition is intended to expand its drug delivery device manufacturing capabilities and support production of current and next‑generation immunology and neuroscience medicines. In addition, AbbVie has reported a voluntary agreement with the U.S. administration that includes commitments for U.S.-based R&D and capital investments, along with expanded direct‑to‑patient offerings for certain medicines.

Oncology research and development

AbbVie describes a significant focus on oncology, particularly in difficult‑to‑treat cancers. The company reports that it is advancing a dynamic pipeline of investigational therapies across blood cancers and solid tumors, using modalities such as small molecule therapeutics, ADCs, T‑cell engagers, immuno‑oncology agents, multispecific antibodies and CAR‑T platforms. AbbVie states that it is evaluating numerous investigational medicines in multiple clinical trials and that it collaborates with partners to accelerate development of potential new treatments.

Company communications highlight data from clinical studies of investigational agents such as etentamig (ABBV‑383) and PVEK (pivekimab sunirine), as well as additional studies of venetoclax‑based regimens and epcoritamab combinations. These disclosures illustrate AbbVie’s emphasis on targeted medicines aimed at blood cancers and other malignancies, and its interest in combination regimens that may address disease heterogeneity.

U.S. manufacturing and investment footprint

AbbVie has publicly described a substantial U.S. presence. In a recent announcement, the company stated that it employs approximately 29,000 people in the United States, with more than 6,000 employees at 11 U.S. manufacturing sites, and that it has a presence in all 50 states and Puerto Rico. AbbVie has also announced plans to invest more than $10 billion of capital in the United States over a decade to support innovation and expand manufacturing capabilities and capacity, and in a separate agreement has referenced a commitment to $100 billion in U.S. research and development and capital investments over a similar timeframe.

The planned acquisition of the Tempe, Arizona manufacturing facility and on‑body injector technology is described as part of this broader commitment to U.S. pharmaceutical manufacturing. AbbVie states that this facility will be integrated into its global manufacturing network and will support production of immunology and neuroscience medicines using on‑body delivery systems.

Regulatory filings and capital markets presence

AbbVie files periodic and current reports with the U.S. Securities and Exchange Commission. Recent Form 8‑K filings discuss matters such as financial results guidance, acquired in‑process R&D and milestones expense, and settlement of litigation related to generic manufacturers of upadacitinib tablets, which AbbVie markets as RINVOQ. These filings confirm that AbbVie’s common stock and several series of senior notes are registered under Section 12(b) of the Securities Exchange Act and listed on the New York Stock Exchange.

AbbVie also issues press releases about upcoming earnings conference calls and presentations at healthcare and investor conferences. These communications typically reiterate the company’s mission, therapeutic focus areas, and its combination of pharmaceutical and aesthetics portfolios.

Patient- and community-focused initiatives

In addition to its therapeutic and financial disclosures, AbbVie has described initiatives aimed at patients and broader communities. For example, the company has supported a short film titled “Second Winds”, which follows individuals living with chronic lymphocytic leukemia and highlights their experiences. AbbVie presents this project as part of its commitment to people affected by blood cancers, alongside its scientific work in oncology.

AbbVie has also announced an agreement with the U.S. administration that includes providing low prices in Medicaid for certain medicines and expanding direct‑to‑patient offerings through a program referred to as TrumpRx. According to the company, this agreement is intended to advance access and affordability while supporting continued pharmaceutical innovation in the United States.

Stock and debt securities

According to recent SEC filings, AbbVie’s securities registered under Section 12(b) of the Exchange Act include:

• Common Stock, $0.01 par value (trading symbol: ABBV) listed on the New York Stock Exchange.
• 0.750% Senior Notes due 2027 (ABBV27) listed on the New York Stock Exchange.
• 2.125% Senior Notes due 2028 (ABBV28) listed on the New York Stock Exchange.
• 2.625% Senior Notes due 2028 (ABBV28B) listed on the New York Stock Exchange.
• 2.125% Senior Notes due 2029 (ABBV29) listed on the New York Stock Exchange.
• 1.250% Senior Notes due 2031 (ABBV31) listed on the New York Stock Exchange.